INTERIM REPORT JANUARY – JUNE 2026

Perpetua Medical reported Q2 2026 net revenue of 5,963 KSEK versus 2,700 KSEK, but operating loss widened to -3,095 KSEK from -538 KSEK. Cash flow deteriorated to -3,456 KSEK (from -1,224 KSEK) and cash remained at 16,828 KSEK versus 5,989 KSEK. EPS was -0.36 SEK (-0.16), indicating continued losses despite revenue growth.

Analysis

The key market mechanism here is not top-line growth; it is runway compression. A revenue inflection that is not accompanied by operating leverage usually forces equity financing before the model proves self-funding, and that tends to cap upside in small-cap medtech because every rally improves the terms of the next raise. In the next 1-2 quarters, the stock should trade less on growth optics and more on the probability of dilution, especially if management keeps spending ahead of scale.

Second-order, this can pressure vendors and distributors because counterparties start demanding tighter payment terms when a microcap balance sheet is thin. If the company is reliant on a narrow set of customers, the growth rate may also be less durable than headline sales imply: one or two accounts can create a false sense of commercial momentum, then normalize quickly. The practical signal to watch is whether gross margin and opex discipline improve faster than revenue, because that is what would convert growth into a lower cost of capital.

The contrarian view is that the market may over-penalize a business that is still in the early monetization phase. If the next update shows operating loss flattening while revenue continues to scale, the equity could rerate sharply because the financing overhang collapses. But absent that evidence, the base case remains a 1-3 month dilution watch rather than a fundamental re-rate story.

Key Decisions for Investors

• No outright long: avoid initiating exposure to Perpetua Medical until the next update shows operating loss growth materially slower than revenue growth; otherwise the 3-6 month path is dominated by financing risk rather than earnings power.
• If trading the theme, short a small-cap healthcare financing-risk basket via XBI on rallies and use Perpetua as a sentiment canary; thesis is that pre-profit healthcare names with weak runway get de-rated first when capital markets tighten.
• Set an alert for any announced equity issue, convertible, or rights offering over the next 1-2 quarters; that is the clearest falsifier for a bullish interpretation and would likely reset valuation lower immediately.
• Watch for a gross margin inflection in the next report: if margins expand while opex stays flat, the name can work for a 6-12 month momentum trade; if not, the growth story is likely self-funding negative.
• If liquidity is a concern, wait for post-result weakness rather than chasing strength; in microcaps with burn > cash generation, the better entry is often after a financing overhang is partially priced in.